Please login to the form below

Not currently logged in
Email:
Password:

Audentes’ rare disease gene therapy programme delayed after third patient death

Third patient death caused by gastrointestinal bleeding

Audentes Therapeutics has indefinitely delayed plans to seek regulatory approval for its rare disease gene therapy after the death of a third patient involved in a clinical trial of the drug.

This was the third death of a patient involved in the Audentes’ ASPIRO clinical trial, which is evaluating its AT132 gene therapy in patients with X-linked myotubular myopathy (XLTM), a rare neuromuscular disease.

XLTM mainly affects males and causes muscle weakness that ranges in severity from mild to life-threatening. In severe forms of the disease, the weakened muscle make breathing difficult and can lead to respiratory failure. The genetic disorder has a mortality rate of around 25% by the age of ten.

AT132 is an aden-associated virus (AAV) based gene therapy that is designed to deliver the MTM1 gene deficient in XLMTM. According to Audentes, preliminary findings show that the immediate cause of death of the third patient was gastrointestinal bleeding.

The patient ws one of three study participants who had received AT132 at a dose of 3x1014 vg/kg, the higher dose, who subsequently began to demonstrate signs of liver dysfunction within three to four weeks after initial dosing.

The three patients also demonstrated evidence of pre-existing hepatobiliary disease, although over half of the patients enrolled in the study also showed evidence of the same pre-existing conditions.

Audentes, which was bought by Japanese pharma company Astellas last year, was forced to put the ASPIRO trial on hold in June after disclosing the first two patient deaths.

“Audentes, together with the ASPIRO investigators and independent Data Monitoring Committee, continues to closely monitor all patients enrolled in the study. Additionally, Audentes’ investigation into why these three patients developed progressive liver dysfunction is ongoing,” the company said in a statement.

Although the study is currently on hold, Audentes maintained that there are no other patients involved in the trial that are known to be experiencing similar liver disfunction.

The company plans to provide further information on the ASPIRO programme based on both ongoing data collection and future regulatory status updates.

Article by
Lucy Parsons

24th August 2020

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics